← DPP-4 inhibitors × body weight & composition

TrialDiabetes care2014

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

Bo Ahrén et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 1,012 people · 2014

Randomised comparison

Lowered body weight & composition

−1.21kg−1.68 to −0.74

As reported

difference −1.21 kg, 95% CI −1.68 to −0.74

One number in the abstract

the abstract, start to end

… for each were as follows: albiglutide -1.21 kg (95% CI -1.68 to -0.74), …

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−1.21−1.68 to −0.74
GLP-1 receptor agonistsDPP-4 inhibitorsSulfonylureas & glinidesBody weight & composition

DPP-4 inhibitors × body weight & compositionhelps?mixed

unlikelylikely
0.500.43 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.910.91 without it

Sulfonylureas & glinides × body weight & compositionhelps?mixed

unlikelylikely
0.270.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

97 papers cite itlatest 60 shown

2014
…
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 24898304